China Coronary Stents Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Coronary stents are small mesh tubes implanted during percutaneous coronary intervention to prop open narrowed or blocked arteries, with China's market serving one of the world's largest patient populations suffering from coronary artery disease. The sector has evolved significantly since China approved its first domestically produced stent in the early 2000s, transitioning from imported device dependence to a market where local manufacturers play leading roles. Drug-eluting stents, which release medication to prevent arterial re-narrowing, have become the clinical standard following decades of clinical evidence supporting their efficacy over earlier bare metal designs.

• •The market encompasses bare metal stents, drug-eluting stents, and bioresorbable vascular scaffolds, with clinical guidelines now favoring drug-eluting platforms for most patient presentations
• •China represents the Asia-Pacific region's largest coronary stent market by volume and value, driven by one of the world's highest burdens of cardiovascular mortality
• •Regulatory reforms and domestic manufacturing expansion have transformed China from a net importer to a significant domestic producer and exporter of interventional cardiology devices

The rising prevalence of cardiovascular disease, connected to dietary shifts, reduced physical activity, and rapid urbanization, has expanded the pool of patients eligible for percutaneous coronary intervention procedures across China's healthcare system. China's aging demographic, with growing cohorts of citizens reaching ages where coronary artery disease risk increases substantially, ensures sustained demand for stent implantation services over the forecast horizon. Government policy interventions including centralized procurement programs and expanded medical insurance coverage have simultaneously reduced per-procedure costs for patients while accelerating adoption rates in previously underserved regional hospitals.

• •Centralized volume-based procurement programs implemented across Chinese provinces have dramatically reduced stent prices while standardizing clinical quality and expanding hospital formulary access
• •The National Medical Products Administration has streamlined approval pathways for domestically developed medical devices, enabling local companies to accelerate new product introductions
• •Rising healthcare expenditure and expanded basic medical insurance coverage have increased procedure volumes in tier 3 and 4 cities where cardiac intervention rates previously lagged coastal regions

Drug-eluting stents command the dominant market share due to clinical trial evidence demonstrating superior long-term outcomes compared to bare metal alternatives, though pricing pressure from procurement programs has narrowed price differentials between generations of drug-eluting technology. Regional demand patterns reflect China's healthcare infrastructure distribution, with tier 1 and 2 cities historically accounting for the majority of procedure volumes while tier 3 and 4 markets represent the fastest growth opportunity. The continued expansion of catheterization laboratory capacity in county-level hospitals is gradually dispersing procedure growth beyond traditional medical hubs.

• •Product segmentation favors drug-eluting stents, with bare metal stents now largely confined to specific clinical indications and cost-constrained settings
• •Regional demand remains concentrated in eastern coastal provinces and major metropolitan areas, though central and western regions are experiencing accelerating growth as hospital infrastructure investments mature
• •Bioresorbable vascular scaffolds occupy a niche premium segment, with adoption limited by reimbursement constraints and ongoing clinical evaluation of long-term outcomes

What are the recent trends and outlook?

The market is expected to sustain its 6.8% compound annual growth rate through 2030 as procedure volume expansion in emerging regional markets partially offsets pricing stabilization following centralized procurement implementation. Intravascular imaging modalities including intravascular ultrasound and optical coherence tomography are becoming integral to complex lesion optimization, creating secondary demand drivers within the broader interventional cardiology ecosystem. Bioresorbable scaffolds and fully absorbable stent platforms represent the next frontier of clinical differentiation, though widespread adoption awaits stronger clinical evidence and reimbursement pathway establishment.

• •Expanding catheterization laboratory infrastructure in county-level hospitals across China's central and western provinces is projected to drive procedure volume growth even as per-unit pricing stabilizes
• •Integration of intravascular imaging guidance with stent implantation is becoming standard of care for complex coronary lesions, supporting ancillary device market expansion
• •Domestic manufacturers are increasingly pursuing international regulatory approvals and export market development as China's stent production capacity exceeds domestic demand requirements